Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-04-29 00:00:00 ET · period of report 2024-04-25 · accession 0001601830-24-000045 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-29 | 2024-04-25 | RXRX | Marriott Tina | Pres, COO | S - Sale+OE | $7.67 | -3,000 | 543.2K | -0.5% | -$23.0K |
| D | 2024-04-29 | 2024-04-25 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $1.06 | +3,000 | 546.2K | +0.6% | +$3,180 |
| D | 2024-04-29 | 2024-04-25 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $0.00 | -3,000 | 485.0K | -0.6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-04-25 | S | D | 3,000 | $7.67 | 543,231 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $7.5 to $7.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Class A Common Stock | 2024-04-25 | M | A | 3,000 | $1.06 | 546,231 | D | — | — | (F2) Since the Reporting Person's last ownership report, she has transferred 96,751 shares of RXRX Class A Common Stock to her former spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by her former spouse. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-04-25 | M | D | 3,000 | $0.00 | 485,000 | D | $1.06 · — to 2028-07-22 | 3,000 Class A Common Stock | (F4) Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. |